Form 4: Labcorp EVP Gains 1,584 Shares; 451 Withheld for Taxes

On March 26, 2026, Labcorp EVP Bryan T. Vaughn received 1,584 shares from a 2023 performance award and had 451 shares withheld for taxes, ending with 6,745.5702 shares owned directly.

Summary

• On 03/26/2026, EVP, Diagnostics Bryan T. Vaughn acquired 1,584 Labcorp common shares at $0 via a vested performance award.
• Also on 03/26/2026, 451 shares were disposed (withheld) at $268.38 per share to satisfy tax obligations.
• Direct beneficial ownership after the transactions is 6,745.5702 shares; ownership immediately after vesting and before withholding was 7,196.5702 shares.
• The performance award was granted on 02/07/2023 and related to performance for the three-year period ended 12/31/2025.
• No open-market purchases or sales were reported; transactions reflect award vesting and tax withholding mechanics.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine insider award vesting with a modest net increase in holdings; neutral to slightly positive signaling, with limited price impact.

Positives

• Performance-based equity award vested for an executive, signaling completion of the 3-year performance period through 12/31/2025.
• Net increase in insider holdings of 1,133 shares (1,584 acquired less 451 withheld).
• Post-transaction direct ownership stands at 6,745.5702 shares, indicating continued alignment with shareholders.

Negatives

• 451 shares were disposed of to cover tax withholding at $268.38 per share.
• No discretionary open-market purchase; equity received via award vesting rather than a buy signal.

Future Outlook

No forward-looking statements or guidance provided.

Management Comments

• Shares were acquired on 03/26/2026 pursuant to a performance award granted on 02/07/2023, relating to performance during the three-year period ended 12/31/2025.
• Stock withholding was executed to satisfy tax withholding obligations.

Industry Context

StockSavvy.ai notes that executive equity vesting and associated tax withholding are routine across diagnostics and life-science tools companies; this reflects standard long-term incentive mechanics rather than discretionary insider buying.

Comparison to Industry Standards

• The vesting size (1,584 shares) is consistent with EVP-level PSU/RSU vesting at large diagnostics and life-science firms such as Quest Diagnostics (DGX) and Thermo Fisher (TMO), where EVP awards commonly vest in the low-thousands of shares subject to performance.
• Use of share withholding at market price to cover taxes is standard practice under U.S. equity plan administration for peers in the sector.
• Absence of open-market buying contrasts with occasional insider purchases seen at some peers; award vesting alone is generally viewed as neutral-to-slightly-positive for signaling.

Stakeholder Impact

• Net increase of 1,133 insider shares may be viewed as modestly aligning executive incentives with shareholders.
• Tax withholding reduced shares delivered to the executive by 451, a standard non-cash settlement for obligations.
• No dilution or cash impact disclosed; transactions are within the equity compensation plan framework.
• No operational or financial guidance changes indicated.

Key Dates

Keywords

Labcorp, LH, Form 4, insider transaction, beneficial ownership, performance award, restricted stock units, equity vesting, tax withholding, Bryan T. Vaughn, EVP Diagnostics, common stock